Feb 9 2010
Synutra International, Inc. (NASDAQ: SYUT), a leading infant
formula company in China and a producer, marketer and seller of
nutritional products for infants, children and adults, today reported
financial results for the Company’s third quarter and nine months ended
December 31, 2009.
“Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations”
Company Continues to Increase Revenues and Maintain Market Share
Revenues for the third fiscal quarter ended December 31, 2009 reached
$96.80 million, an increase of over 400% from $17.7 million in the
year-ago third quarter. The increase is primarily due to the absence of
the Company’s U-Smart product series in the year-ago third quarter after
the Chinese government found that eight lots of Synutra’s U-Smart series
of formula products along with certain products of 21 other
manufacturers had been contaminated with melamine in September 2008.
Since the product recall, the Company has been steadily regaining the
lost market share from the incident through a series of strategic
initiatives, including new marketing and sales programs, sales of its
premium line of Super series infant formula products, which accounts for
the majority of segment sales, and sales of surplus milk powder to
industrial customers.
On a sequential basis, revenues in the third quarter increased 48.2%
from $65.3 million in the second quarter ended September 30, 2009. The
increase was primarily due to continued gains in sales of Synutra’s
powdered formula products and sales of surplus milk powder to industrial
customers. According to data released by the Ministry of
Commerce’s Commercial Information Center (CIC), the Company’s market
share has stabilized at approximately 7.0% for the fiscal quarter ended
December 31, 2009, representing a significant increase from the 3.4% as
reported in October 2008, the month immediately following the melamine
contamination incident.
The Company’s powdered formula segment recorded a gross margin of $16.7
million, or 41.6% from net sales of $40.1 million, which was offset by a
loss of $3.8 million on other sales of $56.5 million, which mainly
included industrial surplus milk powder on revenue of $53.4 million for
the fiscal quarter ended December 31, 2009, representing a significant
improvement from fiscal quarters that immediately followed the product
recall. The improvement of gross profit over the same period in 2008 was
driven primarily through sales of the Company’s premium line of Super
series infant formula products. The sales of Super series infant formula
accounted for approximately 59.6% of the volume of sales and 70.9% of
the net sales for the segment for the fiscal quarter ended December 31,
2009. The Company believes that the increasing sales of its Super series
infant formula has led the segment in market recovery and helped to
stabilize the Company’s market position.
The Company generated a gross profit of $12.6 million during the third
fiscal quarter compared to a loss of $9.8 million in the year-ago
quarter. For the third fiscal quarter, the Company reported a net loss
attributable to common shareholders of $9.7 million, or $0.18 per fully
diluted share, compared to a year-earlier net loss of $49.3 million, or
$0.91 per fully diluted share. On a sequential basis, net loss
attributable to common shareholders in the latest quarter decreased from
$14.0 million, or $0.26 per fully diluted share, in the quarter ended
September 30, 2009.
CEO Sees Continued Market Share Gains and Return to Profitability
Liang Zhang, Chairman and CEO of Synutra, commented, “The quarterly
gains in revenues and market share are clear signs of the success of our
recovery efforts. During the past quarter, we focused on streamlining
management tools and systems to ensure efficiency and transparency. As a
result, we have been able to optimize our inventory levels both on the
production side and in the distribution channels. We also redeployed
significant resources to support increased promotional activities to our
consumers and beyond the distribution channels, by our field promoters
in the communities and our nutrition education professionals at the
medical and healthcare facilities. With the direct impact of the 2008
melamine incident behind us, sales of our industrial surplus milk powder
abating as our inventory levels are restored to reasonable levels, and
with the success of the comprehensive recovery effort and new sales
initiatives, I have reason to believe that we will be on track for
growth and profitability in the near future and we continue to strive to
regain our leadership position in the market in the months ahead.”
Revenues for the nine months ended December 31, 2009 decreased by 12.7%
to $209.5 million from $239.8 million in year-ago period. The Company’s
gross profits for the nine month period ended December 31,
2009 increased by 46.2% to $44.5 million from $30.4 million for the same
period in the previous year. For the nine month period, the Company
reported a net loss of $33.7 million, or $0.62 per diluted share,
compared to a net loss of $83.4 million, or $1.54 per diluted share, for
the same period in the previous year. The decrease in the Company’s
nine-month revenues was a result of the lingering impact of the product
recall carried out in late 2008 as well as a greater proportion of
rebates to distributors and the additional product discounts provided to
distributors beginning August 2009 as compensation for certain product
promotion activities that were previously handled by the Company.
SOURCE Synutra International, Inc.